{"id":"gsk-mmr-vaccine-priorix","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Parotitis"},{"rate":null,"effect":"Arthralgia/arthritis"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in the body without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This immunological memory protects against infection with wild-type viruses upon future exposure. The vaccine is administered intramuscularly or subcutaneously and typically provides lifelong immunity.","oneSentence":"PRIORIX is a live attenuated vaccine that stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:38.861Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of measles, mumps, and rubella in children and adults"}]},"trialDetails":[{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT06399003","phase":"PHASE3","title":"Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-06-28","conditions":"Measles-Mumps-Rubella","enrollment":1200},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT01681992","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Measles, Mumps, Rubella","enrollment":4538},{"nctId":"NCT02184572","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-25","conditions":"Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine","enrollment":1742},{"nctId":"NCT02880865","phase":"PHASE4","title":"Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2016-10-13","conditions":"Encephalitis, Japanese, Measles, Mumps","enrollment":628},{"nctId":"NCT02173704","phase":"PHASE3","title":"Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-11","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":225},{"nctId":"NCT00454987","phase":"PHASE4","title":"Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-16","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis, Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine","enrollment":288},{"nctId":"NCT01627561","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-15","conditions":"Infections, Papillomavirus","enrollment":148},{"nctId":"NCT00148941","phase":"PHASE3","title":"Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01-06","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":4209},{"nctId":"NCT00861744","phase":"PHASE2","title":"Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":"Rubella, Mumps, Measles","enrollment":1259},{"nctId":"NCT01621802","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-06-21","conditions":"Measles-Mumps-Rubella","enrollment":4011},{"nctId":"NCT01702428","phase":"PHASE3","title":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-09","conditions":"Rubella, Measles, Mumps","enrollment":5016},{"nctId":"NCT00474266","phase":"PHASE3","title":"Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-05","conditions":"Infections, Meningococcal","enrollment":1000},{"nctId":"NCT00892775","phase":"PHASE2","title":"Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":"Measles, Varicella, Mumps","enrollment":501},{"nctId":"NCT00226499","phase":"PHASE3","title":"Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-01","conditions":"Varicella, Chickenpox Vaccines","enrollment":5803},{"nctId":"NCT01777308","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-03","conditions":"Infections, Meningococcal","enrollment":156},{"nctId":"NCT02002156","phase":"PHASE4","title":"A Study of the Interaction Between BCG And MenC Immunisation: BAM","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-06-20","conditions":"BCG Infection, Reaction - Vaccine, Immune Response","enrollment":28},{"nctId":"NCT00578175","phase":"PHASE2","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-20","conditions":"Varicella, Rubella, Mumps","enrollment":1851},{"nctId":"NCT00326118","phase":"PHASE3","title":"Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":433},{"nctId":"NCT00289783","phase":"PHASE3","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-22","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4441},{"nctId":"NCT00871117","phase":"PHASE3","title":"Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-31","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":478},{"nctId":"NCT01245049","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-01","conditions":"Acellular Pertussis, Poliomyelitis, Tetanus","enrollment":387},{"nctId":"NCT00197015","phase":"PHASE3","title":"Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10-06","conditions":"Hepatitis A","enrollment":1474},{"nctId":"NCT00969436","phase":"PHASE3","title":"Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-09","conditions":"Varicella, Rubella, Mumps","enrollment":450},{"nctId":"NCT00751348","phase":"PHASE3","title":"Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-01","conditions":"Measles, Varicella, Mumps","enrollment":475},{"nctId":"NCT02058563","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-01","conditions":"Rubella, Mumps, Measles","enrollment":996},{"nctId":"NCT00871000","phase":"PHASE3","title":"Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-01","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":303},{"nctId":"NCT00345683","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4021},{"nctId":"NCT00263653","phase":"PHASE3","title":"Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":297},{"nctId":"NCT00388440","phase":"PHASE4","title":"Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-11","conditions":"Rubella, Mumps, Measles","enrollment":150},{"nctId":"NCT00406211","phase":"PHASE3","title":"Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-07","conditions":"Rubella, Varicella, Mumps","enrollment":398},{"nctId":"NCT01777529","phase":"PHASE4","title":"Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations","status":"COMPLETED","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2012-10","conditions":"Measles, Mumps, Rubella","enrollment":240},{"nctId":"NCT02724852","phase":"PHASE4","title":"MMR Vaccination Among HIV-infected Adults","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2011-07","conditions":"HIV","enrollment":632},{"nctId":"NCT01738841","phase":"","title":"Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2013-08","conditions":"Mumps, Rubella, Measles","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK MMR Vaccine (PRIORIX)","genericName":"GSK MMR Vaccine (PRIORIX)","companyName":"Shanghai Institute Of Biological Products","companyId":"shanghai-institute-of-biological-products","modality":"Biologic","firstApprovalDate":"","aiSummary":"PRIORIX is a live attenuated vaccine that stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses. Used for Prevention of measles, mumps, and rubella in children and adults.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}